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Abstract
Purpose—Targeted nanotherapies are being developed to improve tumor drug delivery and
enhance therapeutic response. Techniques that can predict response will facilitate clinical
translation and may help define optimal treatment strategies. We evaluated the efficacy of
diffusion-weighted magnetic resonance imaging to monitor early response to CRLX101
nanotherapy (formerly IT-101), and explored its potential as a therapeutic response predictor using
a mechanistic model of tumor cell-proliferation.
Experimental Design—Diffusion MRI was serially performed following CRLX101
administration in a mouse lymphoma model. Apparent diffusion coefficients (ADC) extracted
from the data were used as treatment response biomarkers. Animals treated with irinotecan
(CPT-11) and saline were imaged for comparison. ADC data were also input into a mathematical
model of tumor growth. Histological analysis using cleaved-caspase 3, TUNEL, Ki-67 and H&E
were conducted on tumor samples for correlation with imaging results.
Results—CRLX101 treated tumors at day 2, 4, 7 post-treatment exhibited changes in mean
ADC=16 ± 9%, 24 ± 10% 49 ± 17% and size (TV)=−5 ± 3%, −30 ± 4% and −45 ± 13%
respectively. Both parameters were statistically greater than controls (p(ADC) ≤ 0.02, and p(TV) ≤
0.01 at day 4 and 7), and noticeably greater than CPT-11 treated tumors (ADC=5 ± 5%, 14 ± 7%
and 18 ± 6%, TV=−15 ± 5%, −22 ± 13% and −26 ± 8%). Model-derived parameters for cell-
proliferation obtained using ADC data distinguished CRLX101 treated tumors from controls (p =
0.02).
Conclusions—Temporal changes in ADC specified early CRLX101 treatment response and
could be used to model image-derived cell-proliferation rates following treatment. Comparisons of
targeted and non-targeted treatments highlight the utility of non-invasive imaging and modeling to
evaluate, monitor and predict responses to targeted nanotherapeutics.
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Introduction
Targeted cancer nanotherapies are increasingly being explored as alternatives to
conventional therapeutics. They have the potential to increase treatment efficacy and reduce
treatment-related toxicity (TRT) through improved tumor drug delivery (1). Compared to
conventional therapies, nanoscale therapeutics show increased plasma half-life and can
localize to the tumor mass via targeting mechanisms such as enhanced permeability and
retention (EPR) (2, 3). Recently, the EPR effect has been coupled with surface
functionalization of particles (4) to improve retention in the tumor and target specific tumor
cell subsets. Moreover, evidence exists that nanotherapies can also escape multidrug
resistance pathways (3).
Nanotherapies may prove to be useful for the treatment of malignant lymphoma. Despite
great advances in lymphoma management, over half of the patient population diagnosed
with aggressive non-Hodgkin’s lymphoma, 30–40% with advanced Hodgkin’s lymphoma,
and many with indolent lymphoma still develop resistance or relapse of the disease (5–7).
Several strategies, including multi-drug chemotherapy, immunotherapy and radiation-based
therapies, are currently being explored as salvage regimens (6, 7). Important considerations
during the treatment selection process include the need to minimize TRT as well as the need
to avoid cross-resistance from first-line regimens (6, 8). Thus, the use of targeted
nanotherapies offers an interesting therapeutic alternative.
The nanoparticle CRLX101 (formerly IT-101, Cerulean Pharma Inc.) is a conjugate of a β-
cyclodextrin-based polymer and 20(S)-campthothecin (CPT). CPT is a topoisomerase I
inhibitor with a broad activity spectrum (9). CRLX101 increases the solubility of CPT,
keeps CPT in its active lactone form, improves CPT tumor localization and minimizes CPT-
associated TRT (10, 11). Preclinical in vivo studies of CRLX101 demonstrated its efficacy
in a broad range of solid tumors (6, 12), including subcutaneous and disseminated xenograft
lymphoma models (6). CRLX101 is currently in Phase I and Phase II trials for a variety of
solid tumors (13).
A major challenge for clinical translation of cancer nanotherapies is the effective evaluation
of treatment response. Imaging technologies have been used to monitor responses to
conventional therapy (14). Typical methods rely on changes in tumor size (15, 16).
Morphological imaging using computerized tomography (CT), ultrasound and anatomical
magnetic resonance imaging (MRI) can assess changes in the appearance or growth of tumor
masses. However, such changes often occur at least several weeks after treatment, which
may delay useful modifications of the treatment course. A functional imaging technique,
diffusion MRI (17), is being investigated to evaluate therapeutic responses in animal models
(18, 19) and human clinical studies (20, 21). A quantitative metric derived from these
studies, the apparent diffusion coefficient (ADC), has been shown to be sensitive to tumor
therapy response. Although the diffusion of water within tumors is mediated by many
complex processes, ADC has been demonstrated to be related to tumor cellularity and
extracellular volume (22). Increased ADC values over the course of a treatment time course
are correlated with tumor treatment response to small molecule chemotherapy (18, 19),
adoptive immunotherapy (23) and photodynamic therapy (24).
Mathematical models of cancer growth attempt to predict tumor treatment response on an
individual basis. Modeling adds an extra dimension to clinical management by enabling
prospective, patient-specific adjustments of treatment regimens (25, 26). Non-invasive
imaging data have been applied successfully to models of tumor growth and treatment
response in brain (27, 28) and kidney (29) tumors . These studies demonstrate that
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incorporation of imaging data into mathematical models of tumor growth can provide
insights at the cellular scale that may elude conventional measures of tumor progression,
such as the RECIST criteria (30). Furthermore, since the efficacy of nanotherapies is a
complex function of the drug payload and the carrier’s interaction with the tumor
microenvironment (31), image-based modeling of treatment response may also provide
mechanistic insights into the functioning of nanotherapies in vivo.
The purpose of this study is to determine the feasibility of diffusion MRI to evaluate and
predict early treatment efficacy of the nanotherapy CRLX101. Using a preclinical model of
Burkitt’s lymphoma, we compared the diffusion MRI response of low dose CRLX101 to a
high dose administration of a water-soluble CPT analog, irinotecan (CPT-11), and to
controls. Further, serial diffusion MRI data were incorporated into a mathematical model of
tumor cell proliferation to evaluate its ability to highlight and predict the anti-proliferative
activity of CRLX101 in vivo.
Materials and Methods
Cell culture and human lymphoma xenograft models
Daudi cells (human Burkitt’s lymphoma line) were obtained from the American Type
Culture Collection. Cells were maintained in sterile culture media as previously described
(32). 6 to 8 week old female athymic nu/nu mice (Charles River) were injected with 0.2 mL
of 1:1: mixture of tumor cell suspension in 1% human serum albumin in HBSS (Mediatech)
and Matrigel (BD Biosciences) subcutaneously into their right groin. Approximately 3 × 106
cells were injected for each mouse. Mouse care and experimental procedures were carried
out in accordance with protocols approved by the Animal Care Committees at City of Hope
and Caltech.
In vivo MRI studies
A Biospec (Bruker-Biospin Inc. Billerica, MA) 7T MRI scanner and a home-built birdcage
coil were used for image acquisition. For all imaging sessions, animals were anesthetized
using a 1.3–1.75% isoflurane/air mixture and body temperature was maintained at 35–37◦C
with warmed air flowing through the bore. For anatomical imaging, a rapid-acquisition with
relaxation enhancement (RARE) MRI sequence (TR/TE = 4000/23 ms; RARE factor = 4;
number of averages = 2; field-of-view (FOV) = 35.4 × 35.4 mm2; image matrix = 128 ×
128; slice thickness = 0.754 mm) was used to collect 40 contiguous images across the mouse
torso, allowing tumor visualization.
Treatment monitoring began approximately 21 days post xenograft inoculation, when
tumors reached a size of 300–800mm3. Tumor sizes were determined from region of
interests (ROI) drawn on anatomical MRI for each time point. On the day of treatment, mice
were either injected with: a) 0.9% saline intravenously (i.v), b) 100mg/kg CPT-11
intraperitoneally (i.p) or c) 5mg/kg CRLX101 (i.v., dosages defined here reflect the CPT
equivalent dose). Dosage and treatment cohorts were defined to be consistent with previous
studies of CRLX101 (6, 12). Anatomical and diffusion MRI scans were acquired
immediately before treatment (day 0, baseline), 2, 4 and 7 days post-treatment. A total of 19
mice were imaged for this study. CRLX101 and control groups contained 7 mice. Within
those treatment groups, n = 3 were imaged on days 0, 2 and 4 and n = 4 were imaged on
days 0, 2, 4 and 7. All mice in the CPT-11 group (n = 5) were imaged on days 0, 2, 4 and 7.
Diffusion MRI was acquired with a spin-echo diffusion MRI sequence (33) (TR/TE =
3000/25 ms; Δ = 15 ms, δ = 3 ms, with three b values = 0, 800, and 1,200 s/mm2 acquired in
3 orthogonal directions; FOV = 35 × 25 mm2; image matrix = 175 × 125 (zero-filled to 256
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× 125; slice thickness = 0.754 mm). The number of slices acquired in each study was
determined by the tumor size to ensure full coverage of the tumor mass.
ADC maps were generated using diffusion images by fitting to the Stejskal–Tanner equation
(34). The S0 images derived from this analysis were used as templates to segment the tumor
region. Segmentation was done manually using MRIcro (www.mricro.com). Images were
processed using MATLAB (Mathworks Inc).
Modeling tumor growth using diffusion MRI
A simplified logistic model of tumor growth, developed by Atuegwu et. al. (27), was applied
to serial diffusion MRI data in order to estimate tumor cell proliferation rates and tumor cell
number. Since it was not possible to spatially co-register tumor images from multiple time
points on a voxel-by-voxel basis, we only considered ROIs based on the whole tumor.
Briefly, the model is defined by:
[1]
Where N(t) is the number of cells per tumor voxel at time t, N(t1) is the number of cells
present at t = t1, the first time point in the calculation. k is the cell proliferative rate and θ the
cell carrying capacity in the population, here assumed to be the maximum number of cells in
the imaging voxel. If a linear relationship between ADC and cellularity is assumed, ADC
can be related to cell number by:
[2]
and k and N(t) derived by combining [1] and [2]:
[3]
ADCw is the ADC of free water (~3 × 10−3 mm2/s) (35) and ADCmin is the minimum ADC
value calculated from all voxels within a given tumor ROI at t = t1.
The ability of the model to calculate tumor growth for this lymphoma model was tested by
calculating Ncalculated (4) and Ncalculated (7) using day 0/2 and day 2/4 ADC data
respectively. These were compared to Nesstimated (4) and Nesstimated (7), which were
estimated from actual ADC data taken on day 4 and 7.
Cellular proliferation rates (k) were also calculated for each individual using a combination
of ADC data between different time points (day 0/2, 0/4, 2/4, 4/7).
Histological assessment
A separate group of tumor-bearing animals (n = 24) were used to compare histological and
non-invasive imaging results. The animals were treated identically as those in the imaging
studies. At days 0, 2, 4 and 7, animals (n = 2 per time point) from each treatment group were
sacrificed by transcardiac perfusion and tumors were excised. Tumors were placed in 4%
paraformaldehyde overnight, dehydrated in 70% ethanol and subsequently embedded in
paraffin. Paraffin blocks were sectioned at a slice thickness of 4 µm.
Paraffin sections were deparaffinized in xylene and rehydrated through a descending
gradient of alcohol (100%, 95%, 80%, 2 minutes at each concentration) and then water.
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Antigen retrieval was achieved with 10mM Tris, 1mM EDTA and 0.05% Tween 20 pH9.0
for 20 minutes in a steamer and then cooled for 20 minutes. Individual sections from each
treatment cohort and time point were then incubated with primary antibodies to the cellular
proliferation marker Ki-67 (1:200, Neomarkers, RM-9106-SO) or the apoptotic marker
cleaved caspase-3 (CC3, 1:500, Invitrogen, 700182). Immunohistochemistry was performed
on a DAKO Autostainer utilizing a peroxidase DAB method (Leica, Novalink RE7150-K)
followed by counterstaining with hematoxylin.
Staining for apoptosis was performed using a terminal nucleotidyl transferase–mediated nick
end labeling (TUNEL) assay (Roche, Insitu Cell Death Detection Kit) and visualized with a
peroxidase DAB method (Leica, Novalink), followed by counterstaining with hematoxylin.
Corresponding sections were also stained with H&E for overall tumor and cellular
morphology.
All slides were scanned on a Ventana Coreo Slide Scanner for visualization. Three fields per
tumor were analyzed using images obtained at 20x magnification. The percentage of Ki-67
staining was performed with ImmunoRatio (36). Hematoxylin, TUNEL and CC3 slides were
analyzed using ImageJ. Slide images from each respective stain was first extracted using a
color deconvolution (37) plugin; the density of cellular staining was then calculated.
Statistical analysis
Comparison of ADC, tumor size and cell proliferation data among the three treatment
groups was accomplished at each time point using a Kruskal-Wallis test. Multiple
comparison tests were performed with Bonferroni correction after a Mann-Whitney test.
Nesstimated (t) and Ncalculated (t) data were compared using Pearson’s (PCC) and concordance
(CCC) correlation coefficients. A p-value of 0.05 or smaller was considered to be
statistically significant. All analyses were performed using R (http://www.r-project.org/).
Results
Diffusion MRI is sensitive to early CRLX101 treatment response
ADC maps of representative tumor response to the various treatment groups are shown in
Fig. 1. ADC values remained constant for the control animal (top row) over the course of 7
days, with low ADC values (green) over most of the tumor volume at each time point. The
CPT-11 treated animal (bottom row) showed a similar ADC pattern, with low ADC values
over most of the tumor volume across all time points. On day 2 after CPT-11 administration,
clusters of high ADC values (as indicated by red to orange pixels) can be seen around the
edges of the tumor, suggesting CPT-11 response. By day 4 and day 7, small high ADC
clusters still existed, but were approximately the same as seen on day 2. The ADC patterning
remained similar between day 4 and day 7. Compared to the two other treatment cohorts, the
CRLX101 treated tumor (middle row) showed an increase in the ADC value (shift to red)
throughout the whole tumor bulk by day 2 post treatment. This increase continued onto day
4 and 7.
To compare the diffusion MRI response among treatment groups, the mean percentage
change of ADC values from baseline were calculated (see Fig. 2). CRLX101 treated tumors
clearly exhibited increasing tumor ADC values over the course of 7 days compared to
baseline (16 ± 9%, 24 ± 10% and 49 ± 17% change from baseline on day 2, 4 and 7,
respectively). CPT-11 treated tumors also showed a mean increase in ADC values over the
week (5 ± 5%, 14 ± 7% and 18 ± 6%), while control tumors showed a slight decrease in
ADC value compared to baseline (−4 ± 3%, −7 ± 3% and −9 ± 3%). Compared to the
control group, the increases observed in the CRLX101 group were significant on all days
(day 2: p = 0.02, day 4: p < 0.01, day 7: p < 0.01). This was not the case for the CPT-11
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group (day 2: p = 0.4, day 4: p = 0.05, day 7: p = 0.05). ADC increases observed for the
CRLX101 and CPT-11 cohorts were not significantly different.
Diffusion MRI response correlates with traditional measurements of tumor growth
Tumor volume changes as sorted by treatment cohort are shown in Fig. 3. Control tumors
steadily increased in size during the week time course (25 ± 17%, 49 ± 15% and 130 ± 44%
change from baseline on day 2, 4 and 7, respectively), while CRLX101 treated tumors
steadily decreased in size (−5 ± 3%, −30 ± 4% and −45 ± 13%). As with the ADC values,
size decrease in the CPT-11 treated group was less dramatic (−15 ± 5%, −22 ± 13% and −26
± 8%) compared to the nanotherapy-treated group. The tumor size decreases in the
CRLX101-treated group were not significantly different to control on day 2 (p = 0.08), but
were significant by days 4 and 7 (both p < 0.01). In comparison, CPT-11 group tumor size
changes were only significantly different to the control group on day 4 (p < 0.01).
Logistic model of tumor growth can be applied to diffusion MRI of malignant lymphoma
Tumor cell number determined by incorporating diffusion MRI data into a model of tumor
growth is shown in Fig. 4. Ncalculated compared to Nesstimated for days 4 and 7 are shown in
Fig. 4A and 4B–C respectively. The PCC between Ncalculated (4) and Nesstimated (4) is 0.92
(p < 0.0001). The CCC is 0.83. PCC and CCC between Ncalculated (7) and Nesstimated (7) are
0.91 (p < 0.0001) and 0.9 using day 0/4 data and 0.86 (p < 0.0001) and 0.86 using day 2/4
data. These values show a strong relationship between the simulated and estimated data,
demonstrating that the current simplified logistic model can be applied to the diffusion MRI
data generated in this study.
Modeling of tumor proliferation using diffusion MRI show anti-proliferative activity of
CRLX101
Model-derived mean cell-proliferation rates (in units of 1/day) measured from different time
points across treatment groups are shown in Fig. 5. Corresponding boxplots are shown in
Supplementary Fig. 1. CRLX101 treated animals showed negative tumor proliferation rates
across all time points (−0.09 ± 0.05, −0.05 ± 0.03, −0.05 ± 0.01 and −0.11 ± 0.05 for day
0/2, 0/4, 2/4 and 4/7 respectively) and were significantly different (p = 0.02) to control
tumors (0.03 ± 0.02, 0.02 ± 0.01, 0.02 ± 0.02 and 0.04 ± 0.04). CPT-11 animals (−0.04 ±
0.04, −0.02 ± 0.02, −0.06 ± 0.02 and 0.01 ± 0.01) showed negative proliferation rates
between day 0 and day 4. These were significantly different to controls for rates calculated
between day 2/4 (p = 0.03). Interestingly, proliferative rates in CPT-11 tumors calculated
between day 4 and 7 became positive.
Histological assessment of CRX101 response
Treatment-induced changes observed by diffusion MRI were compared with histology (Fig.
6, Supplementary Fig. 2, and Supplementary Table 1). Tumor sections were stained for CC3
to monitor apoptotic activity (Fig. 6A, Supplementary Fig. 2A). Control tumors showed a
low level of staining for CC3 throughout the week (13–110 positive stains/mm2). By
comparison, CRLX101 treated tumors showed a significant increase in CC3 activation
(620±96 vs. 110±92 control, p < 0.01) on day 2. Levels remained significantly increased
compared to time-matched control tumors on day 4 and day 7 (p < 0.01), albeit lower than
day 2 CC3 levels. CPT-11 treated animals also showed significant increases in CC3 levels
compared to control tumors on day 2 (p = 0.03) and 4 (p= 0.02), but were indistinguishable
to time matched controls by day 7 (p = 0.6). Analysis using a TUNEL assay (Fig. 6B,
Supplementary Fig. 2B) to stain for apoptotic cells by detecting 3′ DNA strand breaks (a
biochemical hallmark of apoptosis) showed similar results. CRLX101 treated tumors
showed an increase in apoptotic cells by day 2 of treatment (p < 0.01), which persisted on
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day 4 and day 7. CPT-11 treated tumors showed an intermediate increase in apoptotic cells
by day 2 post-treatment compared to CRLX101 tumors (350±42 vs. 470±57, p < 0.01
compared to controls), but were borderline different to controls by day 7 (p = 0.05). By
comparison, control tumors did not show an increase in apoptotic cell staining throughout
the week (p > 0.4).
Since the active ingredient of CRLX101 and CPT-11, camptothecin, inhibits cellular
proliferation, we also stained tumors using the cellular proliferation marker Ki-67 (Fig. 6C,
Supplementary Fig. 2C). Control tumors maintained high (94.5–98.2%) Ki-67 expression
throughout the week. By comparison, both CRLX101 (46.8±5.2%, p < 0.01) and CPT-11
(51.7±8.2%, p < 0.01) treated tumors showed decreased Ki-67 staining by day 2 of
treatment. Ki-67 expression in CRLX101 tumors remained significantly decreased
compared to controls throughout the week (p < 0.01), while Ki-67 expression in CPT-11
treated tumors trended back towards control values and were borderline different to controls
by day 7 (p = 0.05).
H&E-stained sections from the control group showed a dense cellular pattern that remained
consistent from baseline to day 7 (Fig. 6D, Supplementary Fig. 2D). By comparison,
CRLX101 tumors showed a gradual decrease in cellular density over 7 days (Day 0: 1.2
×104±170 cells/mm2, Day 7: 5.3 × 103±300, p < 0.01). An increase in the number of
amorphous cells can be observed in day 4 and day 7 tumors. CPT-11 tumor sections show a
decrease in cellular density on day 2–4 (Day 0: 1.1 ×104±830 cells/mm2, Day 4: 5.3 ×
103±440, p < 0.01). By day 7, the cellular patterns have trended back towards baseline (9.7
×104±220 cells/mm2).
Discussion
In the current study, diffusion MRI was used to follow the response of a preclinical model of
malignant lymphoma to a targeted nanotherapy (CRLX101) and its small molecule
chemotherapy counterpart (CPT-11). As shown in Figs. 1 and 2, CRLX101 treatment led to
quantifiable changes in ADC as early as day 2. By comparison, CPT-11 treatment also
resulted in detectable changes in ADC, but was attenuated compared to the CRLX101
treatment. This attenuation is similar to what was observed by Lee et al (38), who
demonstrated that attenuation or decrease of ADC values after an initial increase is
indicative of tumor repopulation and emerging resistance. The ADC changes correlated with
tumor growth kinetics, which indicated that CRLX101 treatment resulted in marked tumor
regression while only mild regression was seen with CPT-11 treatment (Fig. 3). Moreover,
the diffusion MRI results reflected histology. CRLX101 and CPT-11 treated tumors showed
increased apoptotic events by day 2. Decreased cellularity was observed in both treatment
cohorts compared to controls across the week. A decrease in the proliferation marker Ki-67
was also observed in both treatment cohorts. This reflects the fact that CPT inhibits cell
proliferation and is concordant with previous studies showing high topoisomerase I
inhibition by CRLX101 and CPT-11 within 48 hours of administration (6). Taken together,
these results confirm the improved efficacy of CRLX101 compared to small molecule
chemotherapy. Furthermore, diffusion MRI was able to demonstrate this improved efficacy
at an early time point.
Other functional imaging techniques are being investigated to monitor early responses in
lymphoma (16). Many of these studies involve nuclear imaging, specifically positron
emission tomography (PET). In particular, 18F-fluoro-2-deoxy-d-glucose (FDG-PET) (39)
and 3'-18F-fluoro-3'-deoxy-L-thymidine (40) are promising imaging biomarkers of
lymphoma response. Interpretation of nuclear imaging studies can be complex, as many
different physiological processes can result in a positive signal during treatment. For
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example, local inflammation following therapy can increase the FDG-PET signal, masking
treatment response (41). Diffusion MRI readouts are less sensitive to such inflammatory
effects (42). Concerns of ionizing radiation over-exposure, especially in lymphoma patients
who may be exposed to serial imaging scans and/or radiation therapy (43) also necessarily
limits the number of nuclear imaging scans that can be obtained from a patient, especially at
early treatment time points.
Although ADC by itself is already a promising imaging biomarker to indicate tumor
response to CRLX101, the availability of ADC datasets from multiple time points enables
mathematical modeling of tumor growth. This potentially allows the prediction of future
treatment response in an individual patient. We applied a simple logistic model of tumor
growth (26) to ADC data. The model makes the simplifying assumption that each imaging
voxel consist only of tumor cells and that ADC changes are entirely due to the reduction in
cellularity; yet it still provides instructive predictions using diffusion MRI datasets. This was
shown by the strong correlation between simulated and estimated tumor cell number at both
day 4 and day 7 (Fig. 4). Proliferation rates generated from this model separated CRLX101-
treated and control groups (Fig. 5) and highlighted the enhanced anti-proliferative effect of
CRLX101 (6). Analysis of proliferative rates across time points may add insights to a
treatment’s mode of action. For example, consideration of the CPT-11 ADC and tumor
growth data alone through day 7 would indicate that the tumor may still be responding to
treatment, albeit less than with the nanotherapy. However, analysis of the proliferation data
indicated that between day 4 and 7 CPT-11 tumors showed a trend toward positive
proliferation rates, suggesting treatment failure. The latter analysis is consistent with
histology; by day 7 Ki-67 and apoptotic staining in CPT-11 tumors were similar to baseline
and control. In contrast, CRLX101 proliferation rates were negative between day 0 and day
2, increased slightly between days 2 and 4 before decreasing again from day 4 to 7. This
observation is consistent with CRLX101 Ki-67 staining, but is not immediately apparent
from looking at ADC changes alone. The reason for this fluctuation of proliferation rate is
unclear; tumor uptake and biochemical activity of CRLX101 have only been followed for up
to 48 hours (6). Histological results showed that CC3 activity for CRLX101-treated tumors
increased between day 0 and 2, decreased between days 2 and 4 before increasing again by
day 7 (Supplementary Fig. 2). CRLX101-treated tumors also showed elevated TUNEL
activity throughout the week compared to both CPT-11 and control. These results suggest
that increased apoptosis contributes to the negative proliferation rates calculated from
diffusion MRI data. The enhanced anti-tumor effect of CRLX101 may act via anti-
angiogenesis and the nanotherapy’s ability to prolong drug release via hydrolytic and
enzymatic cleavage of the cyclodextrin-polymer (11). These factors may be synergistic,
leading to the increased efficacy observed at the latter time point. Techniques that can probe
CRLX101’s dynamic anti-angiogenic effects within the tumor, such as dynamic contrast-
enhanced MRI (44), may be able to elucidate this process.
Since it was difficult to spatially co-register individual tumor images across time points,
imaging data were only analyzed at a whole-tumor ROI level. Thus, the heterogeneity of the
tumor mass, which may also be an important determinant to treatment response, was not
investigated. This may be addressed in future studies by prudent spatial co-registration
across time points. Furthermore, the current model can be integrated into more sophisticated
models (45) of tumor growth. Such models can account for the multiscale factors linking
molecular scale phenomena to morphological tumor changes, including the multiple factors
that can contribute to ADC changes during treatment response (42, 46–48), as well as by
incorporating data acquired concurrently with other modalities (e.g. PET) (49, 50).
In conclusion, we have demonstrated that diffusion MRI can monitor the early response to
CRLX101 treatment in a preclinical model of malignant lymphoma. Modeling of the ADC
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data emphasized the enhanced anti-proliferative effect of CRLX101 compared to controls
and CPT-11. This demonstrates the utility of diffusion MRI for preclinical and clinical
evaluation of targeted nanotherapies such as CRLX101 and suggests that an image-driven
modeling approach can provide insights to their mechanism(s) of action in vivo.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Targeted nanotherapies are being developed for cancer treatment. The advantage of these
therapies over conventional treatments lies in their ability to increase drug uptake in
tumors while reducing treatment-related toxicity. Clinically-applicable biomarkers will
facilitate translation of nanotherapies to the clinic. We evaluated the applicability of
diffusion MRI to monitor CRLX101 (a cyclodextrin-based polymer particle containing
the DNA topoisomerase I inhibitor camptothecin) efficacy in a preclinical model of
malignant lymphoma. Diffusion MRI distinguished animals treated with CRLX101 from
controls as early as day 2 post-treatment. Diffusion MRI also demonstrated the reduced
efficacy of irinotecan compared to CRLX101. Incorporating diffusion MRI data into a
mathematical model of tumor growth allowed prediction of the enhanced anti-
proliferative effect of CRLX101 as compared to irinotecan. These results demonstrate
that serial imaging using diffusion MRI, combined with judicious modeling of imaging
data, provides useful biomarkers to evaluate, monitor and predict the efficacy of targeted
nanotherapies in the clinic.
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Figure 1.
Diffusion MRI is sensitive to early CRLX101 response. Representative ADC maps of Daudi
tumors are shown as color overlays on T2-weighted anatomic MRI images. Diffusion MRI
images were acquired on day 0 (pre-treatment), day 2, day 4 and day 7 for control (top row),
CRLX101 treated (middle row) and CPT-11 treated (bottom row). Diffusion MRI clearly
shows an increased ADC response to CRLX101 throughout the whole tumor mass as early
as day 2 post treatment, compared to CPT-11 treated and control animals (Scale bar = 10
mm).
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Figure 2.
ADC changes over treatment week show efficacy of CRLX101. Percentage change of mean
ADC values compared to baseline is graphed for the three different treatment groups over
one week post treatment. CPT-11 animals showed a slight increase in the ADC values over
the week compared to baseline, while control animals showed a slight decrease. CRLX101
treated animals showed an increase in ADC values at all time points. Compared to the
control cohort, ADC increases observed in CRLX101-treated animals were significant on all
days (day 2: p = 0.02, †, day4: p < 0.01, *, day 7: p < 0.01, *). This was not the case for the
CPT-11 group (day 2: p = 0.4, day4: p = 0.05, ‡, day 7: p = 0.05, ‡). Error bars denote
standard error.
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Figure 3.
Tumor volume size changes over treatment week. Mean tumor sizes, as measured from
anatomical MRI images, are graphed for the three different treatment groups over one week
post treatment. Compared to controls, CRLX101 tumor sizes significantly decreased on both
day 4 and 7 (p < 0.01, *). In comparison, CPT-11 group tumor size changes were only
significantly different to the control group on day 4 (p < 0.01, *). Error bars denote standard
error.
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Figure 4.
A logistic model of tumor growth can be applied to ADC data. (A) Ncalculated (4) (using
ADC data from day 0 and day 2) is compared to Nestimated (4). The linear fit (with 95%
prediction intervals) is also plotted. The Pearson’s correlation coefficient, r, is 0.92 (p <
0.0001) and the concordance correlation coefficient, CCC, is 0.83. (B) Ncalculated (7) (using
ADC data from day 0 and day 4) is compared to Nestimated (7). r = 0.91 (p < 0.0001) and
CCC = 0.9. (C) Ncalculated (7) (using ADC data from day 2 and day 4) is compared to
Nestimated (7). r = 0.86 (p < 0.0001) and CCC = 0.86.
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Figure 5.
Cellular proliferation rates for different treatment groups were calculated by applying ADC
data to a logistic model of tumor growth. Rates were calculated for (A) control, (B)
CRLX101 and (C) CPT-11 animals between day 0/2, day 0/4, day 2/4, and day 4/7. Rates
from CRLX101 animals were negative for all time periods and were significantly different
to controls (p = 0.02, *). Rates for CPT-11 animals were negative between day 0 to day 4,
being significantly different to controls between day 2/4 (p = 0.03, †). By day 4/7, CPT-11
proliferation rates became positive and similar to controls. Error bars denote standard error.
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Figure 6.
Histological assessment of CRLX101 and CPT-11 response. Tumors treated with CRLX101
(5 mg/kg), CPT-11 (100 mg/kg) or saline were harvested for histology on days 0, 2, 4, and
7. Tumor samples were subsequently sectioned and stained with (A) Cleaved caspase-3
(CC3, co-stained with hematoxylin), (B) TUNEL (co-stained with hematoxylin), (C) Ki-67
(co-stained with hematoxylin) and (D) H&E. Compared to controls both CRLX101 and
CPT-11 showed increased CC3 activity and decreased Ki-67 activity by day 2 post-
treatment, shown by the increased staining. This reflects the anti-proliferative, anti-tumor
activity of both agents. CRLX101 treated tumors showed an increased magnitude of these
effects, highlighting its improved efficacy compared to CPT-11. Supplementary Figure 2
and Supplementary Table 1 provide further analysis of the histology (scale bar = 500 µm).
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